Biomedical (3750.T) traded down -0.8 % during a 24 hours period ending at 11:43 PM Central Europe on Monday 26th. One Biomedical stock can currently be bought for about JPY 754 on popular exchanges. Current supply of Biomedical stocks is 8.9 mn. Biomedical has a current market capitalization of JPY 6.7 bn and approximately JPY 4.8 mn worth of Biomedical was traded on exchanges in the last 24 hours. Since last month end, Biomedical has traded -12 % down. Simple moving average of last 200 days is at JPY 823.05. The highest price of past 52 weeks was recorded at JPY 890 on 03/25/2026. 52 weeks low was at JPY 748 on 10/23/2026.
Here is how related stocks have performed in the past 24 hours:
Horiifoodservice (3077.T) traded up 0.17 % and now trades at JPY 1,122. Current market capitalisation for Horiifoodservice is JPY 8 bn. Horiifoodservice has a current price to earnings ratio of 23.6.
Japaniace (9558.T) traded down -1.17 % and now trades at JPY 2,026. Japaniace has a market capitalisation of JPY 8 bn. Japaniace has a current price to earnings ratio of 11.55.
Secure /Tokyo (4264.T) traded down -1.08 % and now trades at JPY 1,268. Current market capitalisation for Secure /Tokyo is JPY 8 bn. Secure /Tokyo has a current price to earnings ratio of 36.07.
Information Strategy & Techn (155A.T) traded down -2.89 % and now trades at JPY 789. Information Strategy & Techn has a market capitalisation of JPY 8 bn.
Tay Two (7610.T) traded down -0.78 % and now trades at JPY 127. Current market capitalisation for Tay Two is JPY 8 bn. Current price/earnings ratio for Tay Two is 6.14.
About Biomedical
Cytori Cell Research Institute Inc. is a biotechnology company that specializes in cellular therapeutics and regenerative medicine. The company, which was formerly known as CytoGenix, was founded in 2004 and has its main office located in Vancouver, Canada. Cytori’s mission is to develop innovative solutions for regenerative medicine and cellular therapeutics by focusing on the utilization of adult stem cells for various therapeutic applications. The company has a strong research and development team that is committed to advancing the field of regenerative medicine through groundbreaking discoveries and advancements in technology. Cytori’s work has contributed significantly to the development of new therapies for various diseases, including heart failure, neurological disorders, and cancer. The company is traded on the NASDAQ stock exchange and its ticker symbol is CYTX.